needlefre
vaccin
deliv
via
mucos
surfac
potenti
betteraccept
vulner
commonli
vaccin
popul
children
also
present
higher
likelihood
gener
necessari
b
cell
respons
optim
protect
portal
entri
infecti
agent
addit
promot
level
system
immun
gener
achiev
convent
inject
secretori
iga
siga
repres
hallmark
immun
respons
mucos
surfac
high
resist
polymer
immunoglobulin
degrad
harsh
environ
mucos
surfac
includ
lumen
gastrointestin
tract
allow
provid
frontlin
protect
portal
entri
infecti
mucos
deliv
subunitvaccin
potenti
stimul
broad
mucos
system
immun
respons
abil
trigger
mucos
iga
reli
addit
effect
vaccin
adjuv
stimul
induct
site
immun
respons
differ
mucos
site
ie
gastrointestin
tract
respiratori
tract
rectal
imprint
express
discret
mucos
home
receptor
adressin
allow
effector
b
cell
home
distinct
mucos
tissu
exampl
intranas
deliveri
vaccin
contain
appropri
mucos
adjuv
promot
specif
immun
respons
airway
howev
safeti
issu
report
follow
intranas
applic
gangliosidebind
toxin
adjuv
sublingu
immun
consid
altern
intranas
rout
vaccin
nonetheless
major
challeng
develop
sublingu
vaccin
identif
appropri
antigenadjuv
previous
shown
bacillu
anthraci
edema
toxin
edtx
effect
adjuv
capabl
promot
system
immun
mucos
siga
respons
nasal
coadminist
vaccin
howev
edtx
test
adjuv
sublingu
vaccin
promot
antigenspecif
igg
respons
bloodstream
fail
elicit
iga
respons
serum
mucos
lack
iga
respons
due
rout
immun
sinc
sublingu
immun
could
induc
respons
vaccin
administ
rang
adjuv
includ
bacteri
enterotoxin
tolllik
receptor
ligand
sting
interestingli
lack
iga
respons
correl
recruit
neutrophil
sublingu
administr
edtx
partial
deplet
neutrophil
sublingu
immun
restor
adjuv
activ
edtx
iga
neutrophil
repres
largest
popul
myeloid
cell
bloodstream
character
initi
respons
inflammatori
event
degranul
cytokin
unfortun
deplet
neutrophil
prior
immun
feasibl
approach
thu
new
strategi
need
improv
efficaci
edtxbas
possibl
sublingu
vaccin
neutrophil
recruit
inflammatori
cytokin
includ
recent
recogn
contribut
chemotaxi
myeloid
cell
product
releas
neutrophil
neutrophil
elastas
inhibitor
nei
class
serin
proteas
inhibitor
target
neutrophil
granul
protein
elastas
commonli
implic
chronic
lung
first
ask
whether
supplement
nei
could
affect
igg
respons
induc
model
sublingu
vaccin
contain
edtx
adjuv
vaccin
target
two
pathogen
reduc
schedul
vaccin
choos
use
ovalbumin
ova
plu
bacillu
anthraci
protect
antigen
pa
combinatori
antigen
test
abil
nei
regul
immun
respons
two
differ
antigen
ova
wellstudi
model
antigen
allow
indepth
analysi
immun
respons
vaccin
thank
larg
number
reagent
avail
studi
ovaspecif
b
cell
respons
hand
use
pa
antigen
allow
us
address
biolog
signific
antibodi
respons
assess
antipa
antibodi
ab
abil
neutral
anthrax
lethal
toxin
letx
analysi
ovaspecif
respons
reveal
nei
increas
magnitud
respons
induc
edtx
effect
evid
earli
day
first
immun
fig
also
found
nei
use
studi
intrins
adjuv
activ
increas
respons
coadminist
antigen
absenc
edtx
fig
analysi
igg
subclass
show
evid
nei
enhanc
coadminist
antigen
absenc
edtx
fig
c
howev
nei
significantli
increas
serum
respons
induc
edtx
adjuv
fig
c
sinc
presenc
nei
differenti
regul
igg
subclass
respons
next
address
potenti
effect
immunoglobulin
isotyp
sublingu
immun
edtx
adjuv
induc
ovaspecif
ige
respons
peak
week
first
immun
day
fig
coadministr
nei
significantli
reduc
magnitud
ige
respons
level
bare
detect
threshold
fig
furthermor
ige
respons
detect
follow
sublingu
applic
nei
antigen
alon
fig
previous
sublingu
immun
edtx
adjuv
fail
induc
ovaspecif
serum
iga
respons
fig
mice
coadministr
antigen
nei
show
detect
minimum
level
serum
iga
respons
day
minimum
serum
iga
level
also
induc
could
measur
day
mice
immun
antigen
ova
pa
plu
ef
interestingli
mice
immun
antigen
ef
presenc
nei
develop
signific
serum
iga
respons
fig
result
summar
show
nei
supplement
improv
kinet
respons
allow
mice
immun
edtx
reach
maximum
titer
quickli
fig
also
show
nei
broaden
antibodi
respons
enhanc
promot
iga
fig
determin
biolog
signific
broader
antibodi
respons
measur
blood
mice
administ
vaccin
supplement
nei
first
assess
antipa
neutral
antibodi
serum
mice
immun
antigen
alon
ova
plu
pa
antigen
plu
nei
antigen
plu
nei
contain
low
compar
level
antipa
neutral
antibodi
fig
hand
antipa
neutral
antibodi
titer
significantli
increas
group
mice
receiv
edtx
nei
fig
also
address
whether
enhanc
neutral
letx
toxic
due
increas
antipa
antibodi
titer
whether
also
result
increas
high
affin
antibodi
antiova
respons
fig
nei
supplement
enhanc
titer
paspecif
iga
respons
mice
edtx
adjuv
fig
importantli
iga
promot
nei
supplement
high
affin
antibodi
fig
previou
studi
shown
major
limit
edtx
adjuv
sublingu
vaccin
inabl
promot
iga
respons
bloodstream
mucos
sublingu
applic
antigen
alon
antigen
plu
nei
stimul
antigenspecif
iga
respons
gut
addit
nei
vaccin
formul
contain
antigen
edtx
result
induct
fecal
iga
respons
detect
week
first
immun
day
increas
one
week
later
day
fig
determin
nei
supplement
promot
gener
iga
respons
mucos
secret
analyz
respons
vagin
wash
unlik
mucos
secret
gastrointestin
tract
vagin
wash
mice
immun
edtx
nei
show
nonsignific
level
antigenspecif
iga
respons
fig
howev
nei
supplement
abl
enhanc
vagin
igg
respons
induc
edtx
adjuv
fig
data
suggest
nei
might
promot
express
gut
home
receptor
iga
produc
cell
elev
igg
antibodi
found
secret
genitourinari
tract
might
come
diffus
igg
blood
import
indic
antipa
ab
respons
measur
mucos
secret
mice
receiv
nei
profil
magnitud
antiova
ab
respons
shown
perform
flow
cytometri
analysi
cytokin
produc
cell
upon
vitro
restimul
ova
elucid
profil
helper
cytokin
support
antibodi
respons
induc
supplement
nei
spleen
cell
mice
immun
antigen
plu
nei
exhibit
frequenc
cell
cell
cell
spleen
cell
mice
receiv
antigen
plu
edtx
fig
frequenc
cell
produc
also
similar
two
group
mice
immun
antigen
plu
nei
exhibit
lower
frequenc
cell
fig
analys
also
show
immun
antigen
plu
nei
promot
higher
frequenc
cell
cell
immun
antigen
plu
edtx
fig
furthermor
nei
edtx
promot
frequenc
antigenspecif
cell
fig
consist
broad
increas
antibodi
respons
coadministr
edtx
nei
significantli
increas
helper
cytokin
respons
includ
tfh
respons
fig
sublingu
rout
current
use
drug
deliveri
allergen
specif
immunotherapi
asit
sublingu
vaccin
theoret
simpl
involv
applic
liquid
rapidli
dissolv
tablet
floor
oral
caviti
like
vaccin
deliv
mucos
site
sublingu
vaccin
potenti
produc
mucos
siga
addit
igg
respons
gener
bloodstream
sublingu
administ
vaccin
less
like
reach
central
nervou
system
tissu
potenti
safer
nasal
vaccin
despit
advantag
identif
appropri
adjuv
formul
remain
requir
develop
sublingu
vaccin
show
supplement
edtx
adjuv
chemic
inhibitor
neutrophil
function
broaden
b
cell
respons
induc
sublingu
immun
promot
antigenspecif
siga
ab
shown
breath
antibodi
respons
induc
edtx
sublingu
adjuv
limit
recruit
neutrophil
mucos
induct
work
first
establish
invers
relationship
presenc
neutrophil
product
iga
mechan
underli
suppress
effect
neutrophil
iga
product
remain
elus
previous
shown
neutrophil
peptid
defensin
enhanc
igg
iga
respons
nasal
coadminist
vaccin
primari
azurophil
granul
neutrophil
contain
defensin
myeloperoxidas
lysozym
three
serin
proteas
neutrophil
elastas
cathepsin
g
proteas
show
inhibit
singl
function
neutrophil
rescu
adjuv
activ
edtx
promot
iga
respons
blood
stream
mucos
tissu
find
signific
use
serin
proteas
inhibitor
might
realist
altern
neutrophil
deplet
strategi
promot
iga
respons
also
rais
question
mechan
behind
neutrophil
elastas
limit
iga
product
neutrophil
elastas
relat
serin
proteas
cathepsin
g
proteinas
shown
regul
cytokin
respons
activ
degrad
cytokin
cytokin
receptor
tolllik
separ
studi
shown
nei
induc
express
mrna
also
aid
baff
respons
spleen
cell
facilit
ig
class
switch
product
regul
express
aid
induct
ig
may
mechan
enhanc
iga
respons
mice
sublingu
immun
edtx
presenc
nei
sublingu
immun
mice
sting
ligand
adjuv
induc
iga
respons
mucos
tissu
genitourinari
howev
neither
cpg
sting
ligand
sublingu
adjuv
induc
siga
secret
gi
tract
ie
fecal
extract
show
ad
edtxbas
sublingu
vaccin
nei
primarili
promot
siga
respons
mucos
secret
gi
tract
signific
level
iga
measur
mucos
secret
although
igg
respons
significantli
increas
vagin
wash
bestdescrib
factor
regul
home
immun
cell
gut
gut
home
receptor
factor
induc
signal
provid
retinoid
acid
product
myeloid
cell
mucos
knowledg
studi
examin
whether
neutrophil
regul
express
gut
home
receptor
worth
note
condit
normal
homeostasi
neutrophil
present
mucos
tissu
concentr
iga
highest
bodi
observ
nei
primarili
promot
siga
gut
suggest
either
directli
stimul
retino
acid
product
stimul
cytokin
promot
enhanc
express
gut
home
iga
immunoglobulin
isotyp
affect
supplement
edtxbas
sublingu
vaccin
nei
fact
nei
also
enhanc
respons
consist
previou
report
elastas
inhibit
matur
function
dendrit
cell
includ
express
costimulatori
molecul
thu
presenc
nei
may
promot
matur
dendrit
cell
express
baff
april
perhap
costimulatori
molecul
ie
enhanc
antibodi
product
anoth
import
point
reveal
present
studi
presenc
nei
improv
qualiti
antibodi
respons
inde
nei
increas
titer
high
affin
igg
iga
antibodi
effect
translat
higher
titer
antipa
neutral
antibodi
find
line
recent
report
neutrophil
regul
germin
center
format
secondari
lymphoid
organ
product
autoreact
plasma
cell
analysi
antigenspecif
helper
cytokin
respons
provid
clue
nei
improv
breath
magnitud
qualiti
antibodi
respons
mice
immun
via
sublingu
rout
edtx
adjuv
found
addit
nei
result
higher
frequenc
cell
produc
cell
produc
cell
produc
tfh
cell
produc
broad
profil
th
cell
cytokin
respons
like
contribut
increas
b
cell
surviv
via
signal
also
consist
observ
other
neutrophil
preferenti
accumul
proxim
cell
secondari
lymphoid
organ
earli
stage
lupu
neutrophil
deplet
acceler
germin
center
studi
nei
may
play
role
neutrophil
deplet
enhanc
develop
germin
center
product
high
affin
antibodi
facilit
differenti
tfh
produc
altogeth
result
show
supplement
sublingu
vaccin
coadministr
nei
improv
kinet
breath
qualiti
antibodi
respons
bloodstream
mucos
tissu
find
rais
question
nei
display
similar
adjuv
activ
vaccin
given
mucos
rout
possibl
nonmucos
vaccin
separ
studi
indic
fact
case
coadministr
nei
modul
immun
respons
induc
intranas
inject
vaccin
attia
z
boyaka
pn
manuscript
prepar
also
worth
note
nei
alon
exhibit
adjuv
activ
enhanc
iga
respons
sublingu
coadminist
vaccin
antigen
effect
appear
extend
immunoglobulin
isotypessubclass
previou
studi
establish
oral
administr
plasma
concentr
nei
alvelestat
peak
hr
elimin
thu
nei
believ
act
quickli
sublingu
immun
elimin
within
hr
futur
studi
investig
underli
mechan
whether
nei
use
univers
strategi
improv
immun
respons
sublingu
vaccin
regardless
adjuv
deliveri
system
experi
perform
accord
guidelin
care
use
laboratori
anim
adopt
nation
institut
health
institut
anim
care
use
committe
iacuc
ohio
state
univers
approv
protocol
effort
made
avoid
unnecessari
pain
distress
minim
anim
suffer
cours
studi
femal
mice
obtain
jackson
laboratori
bar
harbor
mice
maintain
specif
pathogenfre
environ
use
age
experi
approv
perform
accord
guidelin
nih
ohio
state
univers
iacuc
sublingu
immun
perform
previous
administr
pb
solut
mice
anesthet
intraperiton
inject
ketaminexylazin
ml
mgml
gm
bodi
weight
anesthet
mous
receiv
antigen
ie
pa
bacillu
anthraci
protect
antigen
bei
resourc
manassa
va
plu
ovalbumin
grade
v
sigmaaldrich
saint
loui
mo
pb
assess
adjuv
activ
bacillu
anthraci
edema
toxin
result
combin
pa
bacillu
anthraci
edema
factor
ef
group
mice
given
antigen
plu
ef
bei
biosourc
address
effect
nei
supplement
group
mice
given
antigen
plu
alvelestat
selleckchem
houston
tx
antigen
plu
ef
plu
alvelestat
mice
receiv
nei
show
chang
vital
food
consumpt
bodi
weight
group
immun
weekli
interv
consecut
week
day
serum
fecal
pellet
vagin
wash
sampl
collect
weekli
nasal
wash
collect
day
determin
ovaspecif
paspecif
antibodi
titer
elisa
perform
antigenco
plate
describ
briefli
microtit
plate
coat
ova
mgml
pa
detect
ova
paspecif
igg
iga
ab
serum
fecal
materi
extract
serial
dilut
pb
bsa
ad
plate
bind
antibodi
detect
hrpconjug
antimous
chainspecif
antisera
southern
biotech
associ
inc
birmingham
al
biotinconjug
rat
antimous
monoclon
ab
hrpconjug
streptavidin
bd
bioscienc
san
jose
ca
use
measur
igg
subclass
respons
reaction
reveal
addit
watersolubl
hrp
substrat
abt
acid
diammonium
salt
sigmaaldrich
ab
titer
determin
last
dilut
sampl
absorb
control
sampl
mice
assess
iga
level
intestin
secret
freshli
emit
fecal
pellet
normal
homogen
pb
ml
per
g
fece
centrifug
dilut
supernat
use
evalu
antigenspecif
iga
level
describ
high
affin
antibodi
respons
measur
elisa
describ
minor
modif
briefli
plate
coat
pa
incub
dilut
sampl
urea
mm
ad
plate
incub
min
room
temperatur
remov
antibodi
bound
antigen
low
wash
detect
antibodi
ad
remain
step
elisa
conduct
describ
toxin
neutral
assay
perform
previous
briefli
sampl
dilut
ad
macrophag
cultur
cultur
rpmi
supplement
fetal
calf
serum
bacillu
anthraci
lethal
toxin
letx
ie
pa
plu
bacillu
anthraci
lethal
factor
lf
list
biolog
campbel
ca
ad
plate
overnight
incub
mtt
tetrazolium
bromid
sigmaaldrich
ad
assess
viabil
macrophag
function
redox
potenti
toxin
neutral
antibodi
titer
determin
lowest
concentr
sera
protect
macrophag
cytotox
letx
antigenspecif
helper
cell
cytokin
respons
analyz
flow
cytometri
vitro
restimul
intracellular
stain
cytokinespecif
fluoresc
antibodi
briefli
splenocyt
cervic
lymph
node
collect
day
first
immun
restimul
antigen
ie
ova
vitro
previous
day
cultur
cell
subject
extracellular
stain
lineagespecif
antibodi
ie
biolegend
san
diego
ca
fixat
intracellular
stain
tfh
cytokinespecif
antibodi
biolegend
label
cell
analyz
attun
nxt
flow
cytomet
thermo
fisher
scientif
waltham
result
express
mean
standard
deviat
statist
signific
determin
oneway
anova
follow
tukey
posthoc
test
statist
analys
perform
statas
softwar
statacorp
llc
colleg
station
tx
prism
softwar
graphpad
softwar
la
jolla
ca
